Fibroblast biology, fasciitis, retroperitoneal fibrosis, and keloids

Modern Soft Tissue Pathology: Tumors and Non-Neoplastic Conditions

Volumn , Issue , 2010, Pages 181-206

  Miettinen, Markku ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85012124610     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511781049.007     Document Type: Chapter

References (60)

1. McKeehan WL, Wang F, Kan M: The heparan sulfatefibroblast growth factor family: Diversity of structure and function. Prog Nucleic Acid Res Mol Biol 1998; 59: 135-176.
2. Eckes B, Kessler D, Aumailley M, Krieg T: Interactions of fibroblasts with the extracellular matrix: Implications for the understanding of fibrosis. Springer Semin Immunopathol 1999; 21: 415-429.
3. Schurch W, Seemayer TA, Gabbiani G. The myofibroblast: A quarter century after its discovery. Am J Surg Pathol 1998; 22: 141-147.
4. Skalli O, Schurch W, Seemayer T, Lagace R, Montandon D, Pittet B, Gabbiani G. Myofibroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab Invest 1989; 60: 275-285.
5. Nickoloff BJ. CD34. The human progenitor cell antigen (CD34) is localized on endothelial cells, dermal dendritic cells, and perifollicular cells in formalin-fixed normal skin, and on proliferating endothelial cells and stromal spindle-shaped cells in Kaposi’s sarcoma. Arch Dermatol 1991; 127: 523-529.
6. Burgeson RE, Nimni ME. Collagen types: Molecular structure and tissue distribution. Clin Orthop Relat Res 1992; 282: 250-272.
7. Shaw LM, Oslen BR. FACIT collagens: Diverse molecular bridges in extracellular matrices. Trends Biochem Sci 1991; 16: 191-194.
8. Kuivaniemi H, Tromp G, Prockop DJ. Mutations in fibrillar collagens (types I, II, III, and XI), fibril-associated collagen (type IX), and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels. Hum Mutat 1997; 9: 300-315.
9. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2: 1-12.
10. Eswarakumar VP, Lax I, Schlesinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139-149.
11. Konwaler BE, Keasbey L, Kaplan L. Subcutaneous pseudosarcomatous fibromatosis (fasciitis). Am J Clin Pathol 1955; 25: 241-252.
12. Culberson JD, Enterline HT. Pseudosarcomatous fasciitis: A distinctive clinical-pathologic entity: Report of five cases. Ann Surg 1960; 151: 235-240.
13. Price EB Jr, Silliphant WM, Shuman R. Nodular fasciitis: A clinicopathologic analysis of 65 cases. Am J Clin Pathol 1961; 35: 122-136.
14. Allen PW. Nodular fasciitis. Pathology 1972; 4: 9-26.
15. Dahl I, Jarlstedt J. Nodular fasciitis in the head and neck:A clinicopathological study on 18 cases. Acta Otolaryngol 1980; 90: 152-159.
16. Bernstein KE, Lattes R. Nodular (pseudosarcomatous) fasciitis, a nonrecurrent lesion: Clinicopathologic study of 134 cases. Cancer 1982; 49: 1668-1678.
17. Shimizu S, Hashimoto H, Enjoji M. Nodular fasciitis: An analysis of 250 patients. Pathology 1984; 16: 161-166.
18. Kwittken J, Branche M. Fasciitis ossificans. Am J Clin Pathol 1969; 51: 251-255.
19. Wirman JA. Nodular fasciitis, a lesion of myofibroblasts: An ultrastructural study. Cancer 1976; 38: 2378-2389.
20. Montgomery EA, Meis JM.Nodular fasciitis: Its morphologic spectrum and immunohistochemical profile.AmJ Surg Pathol 1991;15:942-948.
21. Perez-Montiel MD, Plaza JA, Dominguez-Malagon H, Suster S. Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue. Am J Dermatopathol 2006; 28: 105-111.
22. Chan JK, Carcangiu ML, Rosai J. Papillary carcinoma of thyroid with exuberant nodular fasciitis-like stroma: Report of three cases. Am J Clin Pathol 1991; 95: 309-314.
23. Sawyer JR, Sammartino G, Baker GF, Bell JM. Clonal chromosome aberrations in a case of nodular fasciitis. Cancer Genet Cytogenet 1994; 76: 154-156.
24. Weibolt VM, Buresh CJ, Roberts CA, Suijkerbuijk RF, Pickering DL, Neff JR, Bridge JA. Involvement of 3q21 in nodular fasciitis. Cancer Genet Gytogenet 1998; 106: 177-179.
25. Donner LR, Silva T, Dobin SM. Clonal rearrangement of 15p11.2, 16p11.2, 16p13.3 in a case of nodular fasctiitis: Additional evidence favoring nodular fasciitis as a benign neoplasms and not a reactive tumefaction. Cancer Genet Cytogenet 2002; 139: 138-140.
26. Velagaleti GV, Tapper JK, Panova NE, Miettinen M, Gatalica Z. Cytogenetic findings in a case of nodular fasciitis of subclavicular region. Cancer Genet Cytogenet 2003; 141: 160-163.
27. Bakac M, Migliavacca E, Stehle JC, McKee T, Delorenzi M, Coindre JM, et al. A gene expression signature that distinguishes desmoid tumors from nodular fasciitis. J Pathol 2006; 208: 543-553.
28. Patchefsky AS, Enzinger FM. Intravascular fasciitis: A report of 17 cases. Am J Surg Pathol 1981; 5: 29-36.
29. Fetsch JF, Brinsko RW, Davis CJ, Mostofi FK, Sesterhenn IA. A distinctive myointimal proliferation ("Myointimoma") involving the corpus spongiosum of the glans penis: A clinicopathologic and immunohistochemical analysis of 10 cases. Am J Surg Pathol 2000; 24: 1524-1530.
30. McKenney JK, Collins MH, Carretero AP, Boyd TK, Redman JF, Parham DM. Penile myointimoma in children and adolescents: A clinicopathologic study of 5 cases supporting a distinct entity. Am J Surg Pathol 2007; 31: 1622-1626.
31. Chung EM, Enzinger FM. Proliferative fasciitis. Cancer 1975:36:1450-1458
32. Kern WH. Proliferative myositis: A pseudosarcomatous reaction to injury. Arch Pathol 1960; 69: 209-216.
33. Enzinger FM, Dulcey F. Proliferative myositis: Report of 33 cases. Cancer 1967; 20: 2213-2223.
34. Kitano M, Iwasaki H, Enjoji M. Proliferative fasciitis: A variant of nodular fasciitis. Acta Pathol Jpn 1977; 27: 485-493.
35. Meis JM, Enzinger FM. Proliferative fasciitis and myositis in childhood. Am J Surg Pathol 1992; 16: 364-372.
36. Dent CD, DeBoom GW, Hamlin ML. Proliferative myositis of the head and neck: Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol 1994; 78: 354-358.
37. Lundgren L, Kindblom LG, Willems J, Falkmer U, Angervall L. Proliferative myositis and fasciitis: A light and electron microscopic, cytologic, DNA-cytometric and immunohistochemical study. APMIS 1992; 100: 437-448.
38. Rose AG. An electron microscopic study of the giant cells in proliferative myositis. Cancer 1974; 33: 1543-1547.
39. Dembinski A, Bridge JA, Neff JR, Berger C, Sandberg AA. Trisomy 2 in proliferative fasciitis. Cancer Genet Cytogenet 1992; 60: 27-30.
40. McComb EN, Neff JR, Johansson SL, Nelon M, Bridge JA. Chromosomal anomalies in a case of proliferative myositis. Cancer Genet Cytogenet 1997; 98: 142-144.
41. Montgomery EA, Meis JM, Mitchell MS, Enzinger FM. Atypical decubital fibroplasia: A distinctive fibroblastic pseudotumor occurring in debilitated patients. Am J Surg Pathol 1992; 16: 708-715.
42. Perosio PM, Weiss SW. Ischemic fasciitis: A juxtaskeletal fibroblastic proliferation with a predilection for elderly patients. Mod Pathol 1993; 6: 69-72.
43. Yamamoto M, Ishida T, Machinami R. Atypical decubital fibroplasia in a young patient with melorheostosis. Pathol Int 198; 48: 160-163.
44. Shulman LE. Diffuse fasciitis with eosinophilia. A new syndrome? Trans Am Assoc Physicians 1975; 88: 70-86.
45. Barnes L, Rodnan GP, Medsker TA, Short D. Eosinophilic fasciitis: A pathologic study of twenty cases. Am J Pathol 1979; 96: 493-517.
46. Shulman LE. Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: A new syndrome. J Rheumatol 1984; 11: 569-570.
47. Doyle JA, Ginsburg WW. Eosinophilic fasciitis. Med Clin North Am 1989; 73: 1157-1166.
48. Varga J, Kahari VM. Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders. Curr Opinion Rheumatol 1997; 9: 562-570.
49. Seal DV. Necrotizing fasciitis. Curr Opin Infect Dis 2001; 14: 127-132.
50. Young MH, Aronoff DM, Engleberg NC. Necrotizing fasciitis: Pathogenesis and treatment. Expert Rev Anti Infect Ther 2005; 3: 279-294.
51. Ormond JK. Idiopathic retroperitoneal fibrosis. JAMA 1960; 174: 1561-1568.
52. Mitchinson MJ. Retroperitoneal fibrosis revisited. Arch Pathol Lab Med 1986; 110: 784-786.
53. Gilkeson GL, Allen NB. Retroperitoneal fibrosis: A true connective tissue disease. Rheum Dis Clin North Am 1996; 22: 23-38.
54. van Bommel EF. Retroperitoneal fibrosis. Neth J Med 2002; 60: 231-242.
55. Miller OF, Smith LJ, Ferrara EX, McAleer IM, Kaplan GW. Presentation of idiopathic retroperitoneal fibrosis in the pediatric population. J Pediatr Surg 2003; 38: 1685-1688.
56. Flieder DB, Suster S, Moran CA. Idiopathic fibroinflammatory (fibrosing/sclerosing) lesions of the mediastinum: A study of 30 cases with emphasis onmorphologic heterogeneity. Mod Pathol 1999; 12: 257-264.
57. Dehner LP, Coffin CM. Idiopathic fibrosclerotic disorders and other inflammatory pseudotumors. Semin Diagn Pathol 1998; 15: 161-173.
58. Hughes D, Buckley PJ. Idiopathic retroperitoneal fibrosis is a macrophage-rich process. Implications for its pathogenesis and treatment. Am J Surg Pathol 1993; 17: 482-490.
59. Niessen FB, Spauwen PH, Shalkwijk J, Kon M. Onthe nature of hypertrophic scars and keloids: A review. Plast Reconstr Surg 1999; 104: 1435-1458.
60. Tuan TL, Nichter LS. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 1998; 4: 19-24.